Skip to main content

Table 1 Comparison between the excluded and the study samples characteristics (total N = 705)

From: Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients

   Excluded sample (n = 113) Study sample (n = 592) Test comparing study sample with excluded sample characteristics
N % or mean (sd) N % or mean (sd)
Treatment (total N = 696) Intensive chemotherapy 7 7 187 32 p* < 0.001
Best supporting care 81 12 179 30
Hypomethylating agents 12 3 175 7
Aracytine low dose 3 78 42 30
Others 1 1 9 1
Patient’s characteristics
 Age Median (inter-quartile range) 80 10 74 12 p # < 0.001
 Sex Men 59 52 364 61 p § = 0.065
Women 54 48 228 39  
 Patients’ SEP (EDI quintile)
(total N = 613)
Q1 – least deprived 3 14 124 21  
Q2 6 29 104 18  
Q3 6 29 127 21 p * = 0.388
Q4 5 24 137 23  
Q5 – most deprived 1 5 100 17  
 Charlson comorbidity index 0 20 19 261 44  
1 11 10 122 21 p § = 0.001
2+ 12 11 104 18  
Undefinable 64 60 105 18  
 Performance status 0/1 26 25 309 52  
2 13 13 91 15 p § = 0.001
3/4 10 10 60 10  
Undefinable 55 53 132 22  
Tumor’s characteristics
 White blood cell counts (tercile) (total N = 599) Tercile 1 – low 1 14 195 33  
Tercile 2 – intermediate 4 57 189 32 p * = 0.393
Tercile 3 – high 2 29 193 33  
Undefinable 0 0 15 3  
 AML ontogeny (total N = 704) AML de novo 36 32 301 51  
Secondary AML (post treatment / MDS) 41 37 268 45 p § < 0.001
Undefinable 35 31 23 4  
 Cytogenetic initial prognosis Favorable/Intermediate 50 44 343 58 p § < 0.001
Unfavorable 26 23 203 34  
Undefinable 37 33 46 8  
  1. p-value for Fisher test *, chi-square test §, or Wilcoxon #